🧬
🧬
🧬
🧬
GenomicDAO Whitepaper
Search
⌃K
Comment on page

REFERENCES

  1. 1.
    “Precision Medicine Market Size, Share | Industry Forecast by 2030.” Emergen Research, 2022, https://www.emergenresearch.com/industry-report/precision-medicine-market. Accessed 8 December 2022.
  2. 2.
    “A Guide to DeSci, the Latest Web3 Movement.” Future, 9 February 2022, https://future.com/what-is-decentralized-science-aka-desci/. Accessed 8 December 2022.
  3. 3.
    S, Keyhani, et al. US Pharmaceutical Innovation in an International Context. 100 ed., vol. 6, Am J Public Health, 2010.
  4. 4.
    Van Arnum, Patricia. “Biopharmaceutical Innovation: Which Countries Rank the Best?” DCAT Value Chain Insights, 13 April 2016, https://www.dcatvci.org/features/biopharmaceutical-innovation-which-countries-rank-the-best/. Accessed 8 December 2022.
  5. 5.
    Mikulic, Matej. “Pharma companies by number of originated drugs 2022.” Statista, 11 May 2022, https://www.statista.com/statistics/791323/top-pharma-companies-by-number-of-originated-drugs/. Accessed 8 December 2022.
  6. 6.
    Deshmukh, Anshool, et al. “Visualizing the World's Biggest Pharmaceutical Companies.” Visual Capitalist, 17 September 2021, https://www.visualcapitalist.com/worlds-biggest-pharmaceutical-companies/. Accessed 8 December 2022.
  7. 7.
    “DNA Testing for Health & Genetics Research.” Sano Genetics | DNA Testing for Health & Genetics Research, 24 August 2019, https://sanogenetics.com/blog/what-is-the-value-of-dna-data. Accessed 8 December 2022.
  8. 8.
    Turner, Brandon E., et al. “Race/ethnicity reporting and representation in US clinical trials: A cohort study.” The Lancet Regional Health - Americas, vol. 11, 2022.
  9. 9.
    “Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001.” PubMed, https://pubmed.ncbi.nlm.nih.gov/15837865/. Accessed 8 December 2022.
  10. 10.
    Popejoy, Alice B., and Stephanie M. Fullerton. “Genomics is failing on diversity.” Nature, no. 538, 29 October 2012, pp. 161-164, https://rdcu.be/c1dsV. Accessed 8 December 2022.
  11. 11.
    “Prescription Medicines: Costs in Context.” North Dakota Legislative Branch, 4 August 2021, https://www.ndlegis.gov/files/committees/67-2021/23_5028_03000appendixe.pdf. Accessed 8 December 2022.
  12. 12.
    Sertkaya, Aylin. “Product Development with Better Clinical Trials.” ASPE, 25 July 2014, https://aspe.hhs.gov/system/files/pdf/77166/rpt_erg.pdf. Accessed 8 December 2022.
  13. 13.
    “Precision Medicine: New Paradigms, Risks and Opportunities - Knowledge at Wharton.” Knowledge at Wharton, 22 September 2016, https://knowledge.wharton.upenn.edu/article/precision-medicine-new-paradigms-risks-opportunities/. Accessed 8 December 2022.
  14. 14.
    Fauber, John. “Kalydeco: A Price Too High to Pay?” Medpage Today, 2 October 2013, https://www.medpagetoday.com/Pulmonology/CysticFibrosis/42018. Accessed 8 December 2022.
  15. 15.
    J., Riley W. “Health disparities: gaps in access, quality and affordability of medical care.” Transactions of the American Clinical and Climatological Association, vol. 123, 2012, pp. 167-174.
Previous
BACKERS & PARTNERS
Last modified 11mo ago